CONSENT TO ASSIGNMENTS, LICENSING AND COMMON OWNERSHIP AND INVENTION MANAGEMENT AGREEMENT FOR A PROGRAMMABLE DNA RESTRICTION ENZYME FOR GENOME EDITING UC Case No: BK-2012-115 CRISPR Reference: CHARPENTIER-2012 Caribou Reference: UC-UV AgreementInvention Management Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledJuly 1st, 2021 Company Industry JurisdictionThis Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing (the “Invention Management Agreement,” “IMA” or “Agreement”) is effective as of December 15, 2016 (the “Effective Date”), and is by and among the following individual and entities:
CONSENT TO ASSIGNMENTS, LICENSING AND COMMON OWNERSHIP AND INVENTION MANAGEMENT AGREEMENT FOR A PROGRAMMABLE DNA RESTRICTION ENZYME FOR GENOME EDITING UC Case No: BK-2012-115 CRISPR Reference: CHARPENTIER-2012 Caribou Reference: UC-UV AgreementInvention Management Agreement • December 16th, 2016 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances
Contract Type FiledDecember 16th, 2016 Company IndustryThis Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing (the “Invention Management Agreement,” “IMA” or “Agreement”) is effective as of December 15, 2016 (the “Effective Date”), and is by and among the following individual and entities:
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT...Invention Management Agreement • December 16th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 16th, 2016 Company Industry JurisdictionThis Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing (the “Invention Management Agreement,” “IMA” or “Agreement”) is effective as of December 15, 2016 (the “Effective Date”), and is by and among the following individual and entities:
AND UNIVERSITY INVENTION MANAGEMENT AGREEMENTInvention Management Agreement • January 10th, 2020
Contract Type FiledJanuary 10th, 2020This Invention Management Agreement ("Agreement" or “IMA”) is made by and between the United States Department of Veterans Affairs ("VA"), as represented by the Technology Transfer Program (“TTP”), Office of Research and Development, having an address at 810 Vermont Avenue NW, Washington, D.C. 20420, and ______University (“University”), having an address at ___________ (individually, “Party” and collectively, “Parties”).